Salama, Youssef
Zhao, Fang
Oliveira, Jennifer L.
Yuan, Ji
Jevremovic, Dragan http://orcid.org/0000-0002-1792-5822
Go, Ronald S. http://orcid.org/0000-0002-8284-3495
Ding, Wei http://orcid.org/0000-0001-9811-4601
Parikh, Sameer A. http://orcid.org/0000-0002-3221-7314
Shah, Mithun V. http://orcid.org/0000-0002-5359-336X
Hampel, Paul J. http://orcid.org/0000-0003-1292-3024
Al-Kali, Aref http://orcid.org/0000-0002-0824-3715
Morice, William G.
Shi, Min http://orcid.org/0000-0002-5741-4293
Article History
Received: 3 October 2021
Revised: 23 January 2022
Accepted: 28 January 2022
First Online: 22 February 2022
Conflict of interest
: S.A.P.: research funding has been provided to the institution from Pharmacyclics, MorphoSys, Janssen, AstraZeneca, TG Therapeutics, Bristol Myers Squibb, Merck, AbbVie, and Ascentage Pharma for clinical studies in which S.A.P. is a principal investigator. He has received honoraria for participation in consulting activities/advisory board meetings for Pharmacyclics, AstraZeneca, Genentech, GlaxoSmithKline, Adaptive Biotechnologies, and AbbVie (no personal compensation); and from Aptitude Health, Curio Science, and MedEd on the Go (with personal compensation). A.A.: received support to the institution from Novartis, Astex, Celgene/BMS, Onconova, Aprea, AstraZeneca. W.D.: research funding received from Merck, AbbVie, Astrazeneca, Bristol Myers Squibb, Octapharma, DTRM pharma directed to the institution where Dr. Ding is a principal investigator. She also has participated in advisory board meetings/steering committees for BeiGene, Octapharma, Alexion, AbbVie, and Merck without personal compensation. Other authors have no conflict of interest.